Literature DB >> 9263340

New and future approaches for spinal cord protection.

L G Svensson1.   

Abstract

The major cause of spinal cord injury, during and after aortic surgery, is based on the occurrence of one or more of the three following events: (1) the duration and degree of ischemia;(2) failure to re-establish blood flow to the spinal cord after the repair; and (3) a biochemically mediated reperfusion injury. Clinically, this manifests either as permanent or reversible paraplegia or paraparesis, or a neurogenic bladder. For more than 40 years, numerous methods have been attempted to prevent paralysis, and some of the newer technical innovations include reducing the duration of ischemia, the use of newer centrifugal pump distal perfusion techniques, localized hypothermia, intrathecal maneuvers, pharmacological agents, angiography, somatosensory-evoked potential monitoring, spinal motor-evoked potential monitoring, hydrogen mapping, not resecting the posterior aortic wall, the use of stents, and a spectrum of various pharmacological agents to prevent reperfusion injury to the spinal cord. Some of these techniques and agent seem to be effective at reducing the risk of spinal cord injury.

Entities:  

Mesh:

Year:  1997        PMID: 9263340

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  3 in total

1.  Prevention of paraplegia in transluminally placed endoluminal prosthetic grafts for descending thoracic aortic aneurysms.

Authors:  H Midorikawa; S Hoshino; F Iwaya; T Igari; K Satou; K Ishikawa
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-12

Review 2.  Fighting spinal cord complication during surgery for thoracoabdominal aortic disease.

Authors:  Yutaka Okita
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-02-10

3.  Thoracoabdominal aneurysm repair: results with 337 operations performed over a 15-year interval.

Authors:  Richard P Cambria; W Darrin Clouse; J Kenneth Davison; Peter F Dunn; Michael Corey; David Dorer
Journal:  Ann Surg       Date:  2002-10       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.